Last update Sept. 7, 2022
Nabilone, a synthetic cannabinoid structurally similar to delta-9-THC in cannabis, has antiemetic properties and is used for the control of nausea and vomiting associated with cancer chemotherapy in patients who have not responded adequately to conventional antiemetics (Martindale). Also in anorexia and weight loss in patients with HIV (DrugBank). Oral administration in two to three daily doses.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (very high percentage of protein binding, and very wide volume of distribution) make it highly unlikely that significant quantities will pass into breast milk.
The elimination half-life of nabilone is 2 hours; that of its metabolites, which are unknown if they are active, of 35 hours. (Martindale)
Nabilone does not alter plasma levels of prolactin. (Mendelson 1984)
A punctual use or at the minimum effective dose could be compatible with breastfeeding by monitoring the infant's neurological and feeding status.
Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2006 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM